Page last updated: 2024-11-11

3,4,4'-trihydroxy-trans-stilbene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID9794567
CHEMBL ID329033
SCHEMBL ID1820186
MeSH IDM0571497

Synonyms (8)

Synonym
4-[2-(4-hydroxy-phenyl)-vinyl]-benzene-1,2-diol
bdbm50045921
4-(4-hydroxystyryl)benzene-1,2-diol
3,4,4''-trihydroxy-trans-stilbene
4-[(e)-2-(4-hydroxyphenyl)ethenyl]benzene-1,2-diol
CHEMBL329033 ,
SCHEMBL1820186
3,4,4'-trihydroxy-trans-stilbene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein kinase LckHomo sapiens (human)IC50 (µMol)19.00000.00021.317310.0000AID164858
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)IC50 (µMol)6.00000.00271.62879.9000AID770333
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1314128Toxicity in rat thymocytes assessed as increase in cell death at 1000 uM measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID1467690Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay relative to AITC2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.
AID416965Inhibition of hydrogen peroxide-induced cell death of BALB/c mouse thymocytes preincubated for 30 mins before hydrogen peroxide challenge measured after 24 hrs by MTT assay2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID1314123Radioprotective activity in rat thymocytes assessed as radio-modification factor pretreated at 100 uM followed by 2 Gy X-ray irradiation measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID416966Inhibition of hydrogen peroxide-induced DNA fragmentation in BALB/c mouse thymocytes at 100 uM preincubated for 30 mins before hydrogen peroxide challenge measured after 6 hrs2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID416970Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID1314126Toxicity in rat thymocytes assessed as increase in cell death at 10 uM measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID416969Prooxidant activity assessed as induction calf thymus DNA damage in presence of 250 uM Cu(II) by ethidium bromide binding based fluorimetric assay2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID416974Induction of DNA fragmentation in human HL60 cells at 50 uM after 48 hrs by ethidium bromide based gel electrophoresis2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID416978Induction of apoptosis in human HL60 cells assessed as cell accumulation at sub-G1 phase at 50 uM after 48 hrs by propidium iodide staining based flow cytometry2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID1314121Radioprotective activity in rat thymocytes assessed as radio-modification factor pretreated at 1 uM followed by 2 Gy X-ray irradiation measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID1314127Toxicity in rat thymocytes assessed as increase in cell death at 100 uM measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID1314125Toxicity in rat thymocytes assessed as increase in cell death at 1 uM measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID1314124Radioprotective activity in rat thymocytes assessed as radio-modification factor pretreated at 1000 uM followed by 2 Gy X-ray irradiation measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID1314122Radioprotective activity in rat thymocytes assessed as radio-modification factor pretreated at 10 uM followed by 2 Gy X-ray irradiation measured after 4 hrs by flow cytometric analysis relative to control2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
A facile and rapid access to resveratrol derivatives and their radioprotective activity.
AID164858Tested in vitro for the inhibition of protein-tyrosine kinase p56lck using angiotensin I (1.2 mM) and [gamma-32P]-ATP (50 pM)1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol.
AID416964Antioxidant effect assessed as inhibition of AAPH-induced oxidative pBR322 plasmid DNA strand breakage at 10 uM by gel electrophoresis2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID416968Inhibition of hydrogen peroxide-induced DNA damage in human PBL cells at 12.5 uM by Comet assay2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Antioxidant-based lead discovery for cancer chemoprevention: the case of resveratrol.
AID1467689Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx at 30 uM preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay relative to resveratrol2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.
AID370921Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB.
AID770333Inhibition of human quinone reductase 2 expressed in Escherichia coli BL21(DE3) using N-methyldihydronicotinamide as co-substrate2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]